These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 29572306)
1. Safety concerns regarding selexipag in pulmonary arterial hypertension. Greene RA Am J Health Syst Pharm; 2018 Apr; 75(7):419-420. PubMed ID: 29572306 [No Abstract] [Full Text] [Related]
2. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. Hardin EA; Chin KM Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464 [TBL] [Abstract][Full Text] [Related]
3. Selexipag for the treatment of pulmonary arterial hypertension. Noel ZR; Kido K; Macaulay TE Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi Kuwano K; Kosugi K; Fuchikami C; Funaki S Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848 [TBL] [Abstract][Full Text] [Related]
8. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension. Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448 [TBL] [Abstract][Full Text] [Related]
9. An evaluation of selexipag for the treatment of pulmonary hypertension. Panagiotidou E; Boutou A; Pitsiou G Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545 [TBL] [Abstract][Full Text] [Related]
10. Safety concerns regarding selexipag in pulmonary arterial hypertension. Noel ZR Am J Health Syst Pharm; 2018 Apr; 75(7):420. PubMed ID: 29572307 [No Abstract] [Full Text] [Related]
11. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag. Verlinden NJ; Walter C; Raina A; Benza RL J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036 [TBL] [Abstract][Full Text] [Related]
12. Selexipag for the treatment of pulmonary arterial hypertension. Sharma K Expert Rev Respir Med; 2016; 10(1):1-3. PubMed ID: 26567613 [TBL] [Abstract][Full Text] [Related]
13. Selexipag for the treatment of pulmonary arterial hypertension. Genecand L; Wacker J; Beghetti M; Lador F Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826 [TBL] [Abstract][Full Text] [Related]
15. Selexipag for the treatment of pulmonary arterial hypertension. Skoro-Sajer N; Lang IM Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. Sardana M; Moll M; Farber HW Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1513-1520. PubMed ID: 27756196 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317 [TBL] [Abstract][Full Text] [Related]
18. Selexipag for the Treatment of Pulmonary Arterial Hypertension. Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV; N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168 [TBL] [Abstract][Full Text] [Related]
19. Selexipag for the treatment of pulmonary arterial hypertension. Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883 [TBL] [Abstract][Full Text] [Related]
20. Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients. Lafuente-Romero A; Rodriguez Ogando A Cardiol Young; 2021 Sep; 31(9):1513-1515. PubMed ID: 33781364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]